Deal Snapshot
VARIAN ACQUIRES ENDOCARE AND ALICON, EXPANDING CANCER CARE SOLUTIONS PORTFOLIO
Tuesday 11 June 2019

US-based oncology company Varian (NYSE: VAR) has acquired Austin, Texas-based Endocare and Hangzhou, China-based, Alicon, to expand its portfolio of multidisciplinary integrated cancer care solutions, the company said. Endocare is a provider of hardware and software solutions supporting cryoablation and microwave ablation, and Alicon, a leader in embolic therapy for treating liver cancer in China.
These acquisitions provide Varian with a leading position in the high-value interventional oncology segment, which is expected to grow from approximately USD 860m in 2019 to over USD 1bn in 20221. Varian will leverage the existing product portfolios of both companies as well as the active R and D programmes powered by teams in Austin and Hangzhou.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 11/06/2019
Target: Endocare, Alicon
Country: USA
Deal Size: 185m (USD)
Sector: Pharmaceuticals
Type: LBO
Financing: Cash
Status: Agreed
Vendor:
Buyer: Varian
Comment:


Options